Axonova Medical Inc.
Philadelphia, PA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3401 Grays Ferry Ave, Philadelphia, PA 19146, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Renerva, Inc. | Pittsburgh, PA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Alume Biosciences Inc. | San Diego, CA | — |
| Yaya Scientific LLC | Franklin, TN | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Ecate, Inc. | Los Angeles, CA | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
| Axion PNI | Atlanta, GA | 339112 Surgical and Medical Instrument Manufacturing |
About the company
Axonova Medical LLC is a partnership or limited liability partnership specializing in innovative solutions for treating major peripheral nerve injuries. The company's primary focus is on developing tissue engineered neuromuscular interfaces (TE-NMIs), which serve as a proxy for degenerating axons following severe nerve injuries. These microstructures are designed to "babysit" affected areas, maintaining innervation of distal nerve and muscle structures until host axons can regenerate and reinnervate the targets. Axonova's technology aims to transform the field of nerve repair by significantly extending the clinical window for peripheral nerve injury treatment. The company has been registered to receive federal government awards since June 19, 2015, and has primarily secured funding through the National Institute of Neurological Disorders and Stroke (NINDS) for its groundbreaking research and development efforts.
Through federal grant awards, Axonova Medical LLC has advanced its TE-NMI technology under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The company received an initial Project Grant (R43NS125892) in January 2022 to develop and characterize TE-NMIs using GalSafe neurons, an FDA-approved xenogeneic source. This grant supported preliminary in vivo studies to evaluate TE-NMI efficacy in a chronic axotomy model in swine. A subsequent Project Grant (R44NS125892), awarded in April 2024, is enabling Axonova to establish CGMP-like manufacturing processes, define critical quality attributes and release criteria, and determine an effective dosing paradigm for the TE-NMIs. This grant also funds in vivo porcine studies to assess TE-NMI efficacy in promoting functional recovery following delayed nerve repair. Additionally, Axonova has received sub-grant awards related to advancing the storage and transport of engineered tissues, indicating the company's involvement in broader tissue engineering applications beyond nerve repair. These projects demonstrate Axonova's commitment to developing cutting-edge solutions for peripheral nerve injuries and its potential to significantly impact clinical practices in nerve repair and regeneration.
Quick answers
Is Axonova Medical Inc. registered in SAM.gov?
Yes. Axonova Medical Inc.'s SAM.gov registration is active through April 30, 2027.
What is Axonova Medical Inc.'s CAGE code?
Axonova Medical Inc.'s CAGE code is 7EM09, and its Unique Entity ID (UEI) is DLUMA6JAZ1K4.
What is Axonova Medical Inc.'s most recent federal award?
Axonova Medical Inc.'s most recent federal grant award is Development of tissue engineered neuromuscular interfaces from galsafe neurons (R44NS125892), from National Institute of Neurological Disorders and Stroke (NIH), on April 23, 2024.
On GovTribe
See Axonova Medical Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors